At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 116 enrolled
Drug / intervention
AzaSite Eye Drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery
In Brief
A Phase 4 clinical trial evaluating AzaSite Eye Drops and Vigamox Eye Drops for Bacterial Infections and 2 related conditions. Completed, enrolled 116 participants across 13 sites.
Detailed Summary
The purpose of this study is to evaluate the drug concentrations in the conjunctiva and aqueous humor of AzaSite™ compared to Vigamox® in subjects undergoing routine cataract surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, Eye Infections, Cataract Extraction
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedDec 18, 2007
Enrollment StartDec 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.5 years ago
Interventions
AzaSite Eye Dropsdrug
One drop two times a day for two days and once a day for the next five days.
Vigamox Eye Dropsdrug
One drop three times a day for seven days